Revalia Bio
Why we are redefining organ donation.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
* | N/A | Grant | |
| Total Funding | 000k | ||
Related Content
Revalia Bio, founded in 2021 by Greg Jensen, is a biotechnology company that has developed a platform for ex vivo human organ research. This platform allows for the study of human organs outside the body, which can help to accelerate the development of new drugs and therapies.
Revalia Bio's business model is based on providing contract research services to the biopharmaceutical industry. The company's clients are pharmaceutical and biotechnology companies that are developing new drugs and therapies. Revalia Bio's platform allows these companies to test their products on human organs in a controlled environment, which can help to reduce the time and cost of drug development.
The company's services include target validation, lead optimization, and preclinical development. Revalia Bio's platform can be used to study a wide range of diseases, including cancer, cardiovascular disease, and infectious diseases.
Revalia Bio has raised a total of $12.3 million in funding from a number of investors, including 2048 Ventures and a prominent, undisclosed life sciences investor. The company is headquartered in New Haven, Connecticut.
Keywords: biotechnology, ex vivo, organ research, drug development, preclinical, human organs, biopharmaceutical, contract research, therapies, platform